KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Jazz Pharmaceuticals (JAZZ) Net Margin: 2009-2025

Historic Net Margin for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to 22.33%.

  • Jazz Pharmaceuticals' Net Margin rose 192.00% to 22.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.58%, marking a year-over-year increase of 193.00%. This contributed to the annual value of 13.81% for FY2024, which is 291.00% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Net Margin of 22.33% as of Q3 2025, which was up 317.89% from -10.25% recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Net Margin registered a high of 22.33% during Q3 2025, and its lowest value of -48.51% during Q2 2021.
  • In the last 3 years, Jazz Pharmaceuticals' Net Margin had a median value of 13.09% in 2023 and averaged 10.85%.
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by 6,925bps in 2021, then skyrocketed by 5,249bps in 2022.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Net Margin stood at -3.61% in 2021, then crashed by 2,108bps to -24.68% in 2022, then spiked by 3,403bps to 9.35% in 2023, then surged by 821bps to 17.56% in 2024, then soared by 192bps to 22.33% in 2025.
  • Its Net Margin stands at 22.33% for Q3 2025, versus -10.25% for Q2 2025 and 17.56% for Q4 2024.